title: Serum anti-p53 antibodies in lung cancer: comparison with established tumor markers.
abstract: As reported earlier, p53 antibodies are detected in the sera of patients with different types of cancer, including lung cancer. In contrast, in the serum of healthy subjects the presence of anti-p53 antibodies is extremely rare. We collected the venous blood samples of 109 patients affected with lung cancer (LC): 57 patients (46 M, 11 F) with non-small-cell carcinoma (NSCLC), 52 others (40 M, 12 F) with small-cell carcinoma (SCLC). Serum p53 antibodies were assayed using ELISA method and all positive sera were confirmed by Western-blot method. In addition, using IRMA methods we assayed serum CEA, TPA, CYFRA21-1 and NSE. Serum p53Ab are detectable (p53Ab-positive) in 35/109 (32.1%) patients with lung cancer. About 17/57 (29.8%) patients affected with NSCLC and 18/52 (34.6%) with SCLC were p53Ab-positive. CEA, TPA, CYFRA21-1 and NSE sensitivity in LC patients (NSCLC+SCLC) is 50.5%, 58.7%, 42.2%, 35.8%, respectively. The lower sensitivity (32.1%) of serum p53Ab is connected with the higher specificity and diagnostic accuracy (100% and 69%, respectively). Out of 35 patients p53Ab-positive, five (14.3%) exhibit only serum p53Ab, while serum values of the established tumor markers were lower than cut-off. Serum p53Ab assessment is a simple and a low-cost assay with a good specificity and diagnostic accuracy that in LC patients can be used at least in association with established tumor markers.
authors.affiliation: Istituto di Patologia Generale e Oncologia, Facoltà di Medicina e Chirurgia Seconda Università degli Studi di Napoli, Via S. Andrea delle Dame 2-80138, Napoli, Italy. rialab@usa.net
authors.forename: M
authors.initials: M
authors.lastname: Cioffi
authors.forename: M T
authors.initials: MT
authors.lastname: Vietri
authors.forename: P
authors.initials: P
authors.lastname: Gazzerro
authors.forename: R
authors.initials: R
authors.lastname: Magnetta
authors.forename: A
authors.initials: A
authors.lastname: D'Auria
authors.forename: A
authors.initials: A
authors.lastname: Durante
authors.forename: E
authors.initials: E
authors.lastname: Nola
authors.forename: G A
authors.initials: GA
authors.lastname: Puca
authors.forename: A M
authors.initials: AM
authors.lastname: Molinari
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000912:Antibodies, Neoplasm / Q000097:blood*; D000951:Antigens, Neoplasm / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology*; D018288:Carcinoma, Small Cell / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology*; D008297:Male; D009367:Neoplasm Staging; D012680:Sensitivity and Specificity; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D016159:Tumor Suppressor Protein p53